Extracellular vesicles (EVs) especially of mesenchymal stem/stomal cells (MSCs) are
increasingly considered as biotherapeutic agents for a variety of different diseases. For …

Over the last three decades, virus-like particles (VLPs) have evolved to become a widely
accepted technology, especially in the field of vaccinology. In fact, some VLP-based …

Introduction: The development of novel complex biotherapeutics led to new challenges in
biopharmaceutical industry. The potential of these particles has been demonstrated by the …

Virus-like particles (VLPs) are increasingly used for vaccine development and drug delivery.
Assembly of VLPs from purified monomers in a chemically defined reaction is advantageous …

The combination of complex nanostructures with carbohydrate polymers can provide a
strong platform for promoting the development of novel drug delivery systems. In this study …

Virus-like particles (VLPs) are self-assembled structures derived from viral antigens that
mimic the native architecture of viruses but lack the viral genome. VLPs have emerged as a …

The present study reports a novel, one-pot, cost-effective, green synthesis route of silver
nanoparticles (AgNPs) from the fruit epicarp extract of Glycosmis pentaphylla (FGP). The UV …

Vaccination continues to be the main approach to protect animals from infectious diseases.
Until recently, all licensed vaccines were developed using conventional technologies …

The downstream processing of virus particles for vaccination or gene therapy is becoming a
critical bottleneck as upstream titers keep improving. Moreover, the growing pressure to …

Vaccines are derived from a variety of sources including tissue extracts, bacterial cells, virus
particles, recombinant mammalian, yeast and insect cell produced proteins and nucleic …